EUVIMEDEUVIMED entdecken
Crossref

Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Platform Elicits Enhanced Humoral and Cellular Immune Responses 2258445

Daria Ivanova, Matthew Lewis, Annie Caplan, Isabella Walters, Emma Snyder, Bryan Steadman, Sky Brubaker

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Daria Ivanova und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Creating effective and thermostable vaccines is of significant relevance for global health. The Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform combines spray drying to encapsulate antigens in a sugar matrix for improved thermostability followed by alumina layer coating for temporal control over in vivo release. Given these advantages, understanding the immune response to ALTA® formulated antigens is important. Here, the immune response to ALTA® formulated antigen was described and compared to a set of adjuvanted liquid formulations. In addition, critical attributes of the ALTA® platform driving its immunogenicity were determined.

Methods

B6 mice were administered OVA antigen formulated with ALTA® platform or liquid adjuvants, including Alhydrogel®, AddaVax™, Alhydrogel®+CpG. The humoral and cell-mediated responses were measured by ELISA and flow cytometry. Fluorescent OVA was utilized to characterize antigen-presenting cells (APCs) at the site of injection and in lymph nodes.

Results

Increased and lasting antigen-specific antibody titers post administration of ALTA® OVA demonstrated robust and durable humoral response. In contrast to adjuvants, ALTA® injected mice produced both IgG2c and IgG1 indicating a more balanced Th1/Th2 response. Importantly, ALTA® OVA elicited robust humoral response at lower doses of aluminum than Alhydrogel®. At all antigen doses, the magnitude of OVA-specific CD8+ T cell response was significantly higher after ALTA® administration. The adaptive immune response and numbers of OVA+ APCs were lower after injection of placebo ALTA® mixed with OVA in diluent than ALTA® formulated OVA. This result demonstrated that antigen encapsulation contributes to the immunogenicity of the platform.

Conclusion

ALTA® formulated protein antigen elicits strong humoral and cell-mediated immunity suggesting a potential broad applicability of the platform to vaccines against various diseases, including intracellular infections and cancer. Funding Source The Gates Foundation INV-064824, The Gates Foundation INV-076862 Topic Categories Vaccines and Immunotherapy (VAC)

Zitieren

APA

Ivanova, D., Lewis, M., Caplan, A., Walters, I., Snyder, E., Steadman, B., & Brubaker, S. (2026). Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Platform Elicits Enhanced Humoral and Cellular Immune Responses 2258445. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.592

Vancouver

Ivanova D, Lewis M, Caplan A, Walters I, Snyder E, Steadman B, et al. Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Platform Elicits Enhanced Humoral and Cellular Immune Responses 2258445. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.592

BibTeX
@article{Ivanova2026,
  author = {Ivanova, Daria and Lewis, Matthew and Caplan, Annie and Walters, Isabella and Snyder, Emma and Steadman, Bryan and Brubaker, Sky},
  title = {Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Platform Elicits Enhanced Humoral and Cellular Immune Responses 2258445},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.592}
}
Kostenlos starten →